MCC
ATNM icon

Malaga Cove Capital’s Actinium Pharmaceuticals ATNM Stock Holding History

Malaga Cove Capital’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,000
Closed -$7K – 149
2019
Q2 		$7K Hold
1,000
– – ﹤0.01% 159
2019
Q1 		$14K Hold
1,000
– – 0.01% 161
2018
Q4 		$12K Sell
1,000
-1,000
-50% -$17.1K 0.01% 161
2018
Q3 		$45K Hold
2,000
– – 0.02% 156
2018
Q2 		$38K Buy
+2,000
New +$25.3K 0.02% 154

Other funds holding ATNM

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Malaga Cove Capital's ATNM Position: Q3 2019 in Review

Malaga Cove Capital sold out of Actinium Pharmaceuticals (ATNM) in Q3 2019, closing a stake of 1,000 shares — an estimated $7K sold.

Malaga Cove Capital first reported a position in ATNM in Q2 2018 and held it in 5 quarters. The position peaked at $45K in Q3 2018. 40 funds tracked by Wall St. Rank hold ATNM as of Q3 2019.

  • Malaga Cove Capital reported no remaining Actinium Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Malaga Cove Capital sold 1,000 Actinium Pharmaceuticals shares in Q3 2019, an estimated $7K.
  • Malaga Cove Capital first reported a position in Actinium Pharmaceuticals in Q2 2018 and held it in 5 quarters.
  • Malaga Cove Capital's Actinium Pharmaceuticals position peaked at $45K in Q3 2018.
  • 40 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2019.

Based on Malaga Cove Capital's 13F filing for Q3 2019, filed 31 Oct 2019.